Viewing Study NCT00343551


Ignite Creation Date: 2025-12-24 @ 11:54 PM
Ignite Modification Date: 2026-02-25 @ 9:44 PM
Study NCT ID: NCT00343551
Status: COMPLETED
Last Update Posted: 2017-02-23
First Post: 2006-06-22
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.
Sponsor: Novartis
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Essential Hypertension View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Hypertension, ambulatory blood pressure, missed dose, aliskiren View